<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sulocton effect was evaluated in 33 patients with symptoms of brain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> during <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty patients received the drug orally for 2 months in doses of 100 mg thrice daily </plain></SENT>
<SENT sid="2" pm="."><plain>Three patients discontinued the treatment earlier (two of them discontinued it because of side effects) </plain></SENT>
<SENT sid="3" pm="."><plain>After two months of treatment a significant improvement was observed in such disturbances important for wellbeing and social contacts as: <z:hpo ids='HP_0000739'>anxiety</z:hpo> and fear, mood <z:hpo ids='HP_0000716'>depression</z:hpo>, disequilibrium of emotion, motivation and initiative </plain></SENT>
<SENT sid="4" pm="."><plain>In many patients <z:hpo ids='HP_0002315'>headaches</z:hpo>, dizziness and <z:hpo ids='HP_0001288'>gait disturbances</z:hpo> disappeared or diminished </plain></SENT>
<SENT sid="5" pm="."><plain>Sulocton was useful in the treatment of patients with cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>